GlassScriptPhysician profile
Monalisa Joseph
NPI 1578849345
$1,727.86
in general payments reported to CMS, 2019-2025
19 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.60 · 2020: $99.93 · 2021: $350 · 2022: $293 · 2023: $304 · 2024: $363 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.41 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $282.15 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $220.66 | 2020-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $192.66 | 2020-2023 | Korsuva, Veltassa |
| Amgen INC. | $155.03 | 2019-2024 | Tavneos |
| Novartis Pharmaceuticals Corporation | $143.22 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $97.05 | 2021-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $96.05 | 2021-2025 | |
| Akebia Therapeutics INC | $68.00 | 2020-2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $67.51 | 2020-2022 | |
| Glaxosmithkline, LLC. | $65.29 | 2022-2023 | Benlysta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.68 | 2024-2025 | Jynarque |
| Boston Scientific Corporation | $55.00 | 2019 | |
| Lilly USA, LLC | $52.72 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $42.71 | 2024-2025 | Purified Cortrophin Gel |
| Nxstage Medical, INC. | $36.93 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $33.69 | 2024 | |
| Ardelyx, INC. | $28.40 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $17.36 | 2022 | |
| Daiichi Sankyo INC. | $14.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monalisa Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.